We are live on ! Find out more

129 hedge funds and large institutions have $2.37B invested in Insmed in 2017 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 56 increasing their positions, 46 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 46

20% more funds holding in top 10

Funds holding in top 10: 56 (+1)

18% more call options, than puts

Call options by funds: $7.19M | Put options by funds: $6.09M

3.03% more ownership

Funds ownership: 96.08%99.11% (+3%)

3% more capital invested

Capital invested by funds: $2.3B → $2.37B (+$65.5M)

12% less funds holding

Funds holding: 146129 (-17)

44% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 36

Holders
129
Holders Change
-17
Holders Change %
-11.64%
% of All Funds
2.93%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.14%
New
20
Increased
56
Reduced
46
Closed
36
Calls
$7.19M
Puts
$6.09M
Net Calls
+$1.1M
Net Calls Change
-$4.16M

INSM Hedge Fund Activity: Q4 2017 in Review

129 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q4 2017, worth a combined $2.37B — up 2.8% from $2.3B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of INSM and 20 opened new positions — a net loss of 16 holders — while 46 trimmed existing stakes and 56 added.

The largest buyer was Janus Henderson Group, adding an estimated $59.2M. The largest seller was Jennison Associates, exiting entirely with an estimated $47M sold.

  • 129 institutional investors held Insmed (INSM) as of Q4 2017, down from 146 in Q3 2017.
  • Funds reported $2.37B of Insmed stock for Q4 2017, up 2.8% quarter-over-quarter.
  • 20 funds opened new Insmed positions in Q4 2017 and 36 closed out, a net change of -16 holders.
  • The largest Insmed buyer in Q4 2017 was Janus Henderson Group, an estimated $59.2M added.
  • The largest Insmed seller in Q4 2017 was Jennison Associates, an estimated $47M sold.

Based on aggregated 13F filings for Q4 2017.